Screener
Janux Therapeutics JANX Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
FAQ
- What is Janux Therapeutics's cash & equivalents?
- Janux Therapeutics (JANX) reported cash & equivalents of $27.77M in Q2 2026.
- How has Janux Therapeutics's cash & equivalents changed year-over-year?
- Janux Therapeutics's cash & equivalents decreased by 47.1% year-over-year, from $52.45M to $27.77M.
- What is the long-term trend for Janux Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Janux Therapeutics's cash & equivalents has grown at a 46.3% compound annual growth rate (CAGR), from $7.81M to $52.33M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Janux Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude